P3, N=547, Completed, Amgen | Active, not recruiting --> Completed

This study represents the largest prevalence assessment of FGFR2b overexpression in G/GEJC using a validated IHC assay. The observed estimates of 36.5% (any 2+/3+) and 16.6% (FGFR2b ≥10% 2+/3+) suggest that FGFR2b is prevalent in a meaningful proportion of patients with advanced G/GEJC.

Experiments on HUVECs further verify the inhibitory effect of FPA144 on vascular endothelial cells. Our findings demonstrate that FPA144 can efficiently inhibit the development of choroidal neovascularization in mice by downregulating CD146 and Yap1.

P1/2, N=0, Withdrawn, Centre Leon Berard | N=87 --> 0 | Not yet recruiting --> Withdrawn

P2/3, N=327, Completed, Amgen Inc. | Active, not recruiting --> Completed

P1, N=16, Completed, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting --> Completed | N=90 --> 16 | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Apr 2027 --> Apr 2026

The primary endpoint is the objective response rate, which is assessed by a blinded independent central review. Translational research is planned to explore the predictive biomarkers and mechanisms of resistance to bemarituzumab by sequencing tumor DNA (PleSSiSion-Neo) and circulating tumor DNA (Guardant360), which are collected at multiple time points.

P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed

P2, N=0, Withdrawn, Institut Cancerologie de l'Ouest | N=49 --> 0 | Trial completion date: Jun 2034 --> Jan 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2029 --> Jan 2026

P2, N=126, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting

P3, N=515, Active, not recruiting, Amgen | Trial primary completion date: Jan 2026 --> Oct 2025

P1/2, N=72, Active, not recruiting, Amgen | Trial completion date: Mar 2028 --> Aug 2026